| Literature DB >> 34171881 |
Priyanka Kadam Halani1, Eden Gelman1, Yvette Duchein2, Nicole Roselli1, Ava Leegant1.
Abstract
OBJECTIVES: The aim of the study was to describe time intervals between pessary maintenance visits in racially diverse women receiving care in a U.S. epicenter of the COVID-19 pandemic. We secondarily aimed to determine whether time interval between pessary changes is associated with adverse outcomes and to identify factors associated with adverse pessary outcomes.Entities:
Mesh:
Year: 2022 PMID: 34171881 PMCID: PMC8808767 DOI: 10.1097/SPV.0000000000001085
Source DB: PubMed Journal: Female Pelvic Med Reconstr Surg ISSN: 2151-8378 Impact factor: 2.091
Demographics and Clinical Characteristics of Study Population
| Age | 77 ± 8.5 |
| BMI | 28.0 ± 5.5 |
| Parity | 3 (2–4) |
| Race | |
| Hispanic | 37 (35.6) |
| Black | 34 (32.7) |
| White | 7 (6.7) |
| Other | 14 (13.5) |
| Declined | 12 (11.5) |
| Preferred language | |
| English | 75 (72.1) |
| Non-English | 29 (27.9) |
| Spanish | 27 (26.0) |
| Bengali | 1 (1.0) |
| Portuguese | 1 (1.0) |
| Insurance type | |
| Medicare | 88 (84.6) |
| % of Medicare with secondary Medicaid coverage | 33 (37.5) |
| Medicaid | 5 (4.8) |
| Private | 10 (9.6) |
| No insurance | 1 (1.0) |
| Living below poverty line, % | 26.2 ± 10.5 |
| History of POP or UI surgery | 5 (4.9) |
| History of hysterectomy | 21 (20.4) |
| Current smoker | 4 (3.9) |
| History of diabetes | 46 (45.1) |
| Hemoglobin A1c | 6.2 ± 2.3 |
| Aspirin use | 45 (43.7) |
| Anticoagulation use | 15 (14.6) |
| Vaginal estrogen use | 39 (37.5) |
| Hormone therapy | 1 (1.1) |
| Sexually active | 19 (18.8) |
| History of erosion | 14 (15.6) |
| Type of pessary | |
| Ring with support | 57 (54.8) |
| Gellhorn | 35 (33.7) |
| Continence ring with support | 10 (9.6) |
| Incontinence dish/continence ring | 2 (1.9) |
| Pessary size, in | 2.7 ± 0.3 |
| Indication for pessary | |
| POP | 92 (88.5) |
| SUI | 2 (1.9) |
| Both POP and SUI | 10 (9.6) |
| Total duration of pessary use, mo | 33.5 (13.0–56.3) |
| Provider type | |
| Nurse practitioner | 82 (78.8) |
| Physician | 22 (21.2) |
| Prolapse stage | |
| 1 | 2 (2.0) |
| 2 | 23 (23.5) |
| 3 | 49 (50.0) |
| 4 | 24 (24.5) |
Data are mean ± SD, median (interquartile range), or n (%).
BMI, body mass index; POP, pelvic organ prolapse; SUI, stress urinary incontinence; UI, urinary incontinence.
Adverse Pessary Outcomes at Baseline Pre–COVID-19 Pandemic Versus Extended Interval During COVID-19 Pandemic
| Adverse Event | Baseline: Pre–COVID-19 Pandemic | Extended Interval: During COVID-19 Pandemic |
|
|---|---|---|---|
| Time between pessary visits, median (IQR), mo | 3.3 (3.0–3.9) | 4.5 (3.7–5.3) | <0.001 |
| Vaginal bleeding | 3 (2.9) | 7 (6.7) | 0.2 |
| Vaginal discharge | 30 (28.9) | 15 (14.4) | 0.003 |
| Vaginal erosion | 8 (7.7) | 7 (6.7) | 0.8 |
| Dislodged pessary | 3 (2.9) | 3 (2.9) | 1.0 |
| Pessary holiday | 5 (4.9) | 7 (6.7) | 0.5 |
| Urinary tract infection | 6 (5.6) | 2 (1.9) | 0.2 |
| Fistula | 0 (0) | 0 (0) | 1.0 |
| Patient-reported symptoms: | |||
| Pain/discomfort | 4 (3.9) | 5 (4.8) | 0.7 |
| Vaginal bleeding | 9 (8.7) | 5 (4.9) | 0.3 |
| Vaginal discharge | 5 (4.8) | 8 (7.7) | 0.4 |
| Urinary difficulty | 2 (1.9) | 1 (1.0) | 0.6 |
| Bowel difficulty | 4 (3.9) | 8 (7.7) | 0.2 |
Data are n (%), unless otherwise specified.
IQR, interquartile range.